<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ateroskleroz</journal-id><journal-title-group><journal-title xml:lang="ru">Атеросклероз</journal-title><trans-title-group xml:lang="en"><trans-title>Ateroscleroz</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-256X</issn><issn pub-type="epub">2949-3633</issn><publisher><publisher-name>НИИТПМ-филиал ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52727/2078-256X-2021-17-2-12-21</article-id><article-id custom-type="elpub" pub-id-type="custom">ateroskleroz-432</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Определение вероятностного времени развития инфаркта миокарда у больных сахарным диабетом 2 типа</article-title><trans-title-group xml:lang="en"><trans-title>Determination of the probable time of myocardial infarction development in patients with type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4832-3197</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ложкина</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Lozhkina</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, проф. кафедры факультетской терапии; кардиолог и куратор отделения для лечения больныхс острым коронарным синдромом Регионального сосудистого центра № 1</p><p>630091, Новосибирск, Красный просп., 52</p><p>630047, Новосибирск, ул. Залесского, 6</p></bio><bio xml:lang="en"><p>630091, Novosibirsk, Krasny av., 52</p><p>630008, Novosibirsk, Leningradskaya str., 113</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1687-4100</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толмачева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolmacheva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> аспирант кафедры факультетской терапии им. проф. Г.Д. Залесского</p><p>630091, Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>630091, Novosibirsk, Krasny av., 52</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5282-6002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воскобойников</surname><given-names>Ю. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Voskoboinikov</surname><given-names>Yu. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р физ.-мат. наук, проф., зав. кафедрой прикладной математики</p><p>630008, Новосибирск, ул. Ленинградская, 113</p></bio><bio xml:lang="en"><p>630089, Novosibirsk, Boris Bogatkov str., 175/1</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, проф., зав. лабораторией молекулярно-генетических исследований терапевтических заболеваний</p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p>630047, Novosibirsk, Zalesskogo str., 6 </p></bio><email xlink:type="simple">medik11@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рагино</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ragino</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, проф., чл.-корр. РАН, руководитель </p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p>630047, Novosibirsk, Zalesskogo str., 6 </p></bio><email xlink:type="simple">ragino@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бравве</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Bravve</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, проф., главный врач; профессор кафедры экономики и управления в здравоохранении</p><p>630091, Новосибирск, Красный просп., 52</p><p>630047, Новосибирск, ул. Залесского, 6</p></bio><bio xml:lang="en"><p>630091, Novosibirsk, Krasny av., 52</p><p>630008, Novosibirsk, Leningradskaya str., 113</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО Новосибирский государственный медицинский университет Минздрава России;&#13;
ГБУЗ НСО Городская клиническая больница № 1<country>Россия</country></aff><aff xml:lang="en">Novosibirsk State Medical University of Minzdrav of Russia;&#13;
Novosibirsk State University of Architecture and Civil Engineering<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО Новосибирский государственный медицинский университет Минздрава России<country>Россия</country></aff><aff xml:lang="en">Novosibirsk State Medical University of Minzdrav of Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБОУ ВО Новосибирский государственный архитектурно-строительный университет Минобрнауки России<country>Россия</country></aff><aff xml:lang="en">Research Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН<country>Россия</country></aff><aff xml:lang="en">City Clinical Hospital № 1<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>09</day><month>08</month><year>2021</year></pub-date><volume>17</volume><issue>2</issue><fpage>12</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ложкина Н.Г., Толмачева А.А., Воскобойников Ю.Е., Максимов В.Н., Рагино Ю.И., Бравве Ю.И., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ложкина Н.Г., Толмачева А.А., Воскобойников Ю.Е., Максимов В.Н., Рагино Ю.И., Бравве Ю.И.</copyright-holder><copyright-holder xml:lang="en">Lozhkina N.G., Tolmacheva A.A., Voskoboinikov Y.E., Maksimov V.N., Ragino Y.I., Bravve Y.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ateroskleroz.elpub.ru/jour/article/view/432">https://ateroskleroz.elpub.ru/jour/article/view/432</self-uri><abstract><p> Цель исследования – создать способ оценки вероятностного времени развития острого инфаркта миокарда (ОИМ) у больных с подтвержденным диагнозом сахарного диабета (СД) 2 типа. </p><sec><title>Материал и методы</title><p>Материал и методы. Работа проводилась на базе Регионального сосудистого центра № 1 г. Новосибирска. Выполнен ретроспективный анализ данных 115 пациентов с диагнозом ОИМ в сочетании с верифицированным СД 2 типа, госпитализированных в период с 2018 по 2019 г. У всех включенных в исследование оценивались клинико-демографические, анамнестические, физикальные, функциональные, лабораторные данные в соответствии с  федеральным стандартом диагностики и лечения этой  патологии. Характер и длительность течения, медикаментозная терапия СД анализировались по  медицинским документам и базам данных. Построена регрессионная модель оценки вероятностного времени развития ОИМ у больных с СД 2 типа.</p></sec><sec><title>Результаты</title><p>Результаты. В авторскую модель оценки вероятностного времени развития ОИМ у больных с СД 2 типа вошли восемь показателей, которые значимо коррелировали с  зависимой переменной и слабо коррелировали между собой: пол пациента, хроническая болезнь почек со снижением скорости клубочковой фильтрации до 60 мл/мин/1,73 м2, диабетическая ретинопатия,  верифицированная периферическая полинейропатия,  курение сигарет, одна пачка и более, число гемодинамически значимых стенозов коронарных артерий  по результатам селективной коронарографии, применение  инсулина короткого и длительного действия в составе сахароснижающей терапии. </p></sec><sec><title>Заключение</title><p>Заключение. Показана высокая предсказательная  способность авторского подхода определения  индивидуального прогнозного времени развития ОИМ у  больного, страдающего СД 2 типа. Внедрение в реальную  клиническую практику разработанного метода позволит персонифицированно вести пациентов СД 2 типа и снизить  индивидуальный риск такого грозного сердечно-сосудистого осложнения, как ИМ. </p></sec></abstract><trans-abstract xml:lang="en"><p> Aim of the study was to create a method for assessing the probabilistic time of development of acute myocardial infarction (AMI) in patients with a confirmed diagnosis of type 2 diabetes mellitus (DM). </p><sec><title>Material and methods</title><p>Material and methods. The work was carried out on the basis of the Regional Vascular Center No. 1 (Novosibirsk). A retrospective analysis of the data of 115 patients diagnosed with AMI in combination with verified type 2 DM who were hospitalized in the period from 2018 to 2019 was performed. In all patients included in the study, clinical and demographic, anamnestic, physical, functional, and laboratory data were assessed in accordance with the federal standard for the diagnosis and treatment of this pathology. The nature and duration of the course, drug therapy for diabetes mellitus were assessed according to medical documents and databases. Further, a  regression model was built for assessing the probabilistic time of development of AMI in patients with type 2 DM.</p></sec><sec><title>Results</title><p>Results. The author’s model for assessing the probabilistic time of development of acute myocardial infarction in patients with type 2 DM included eight indicators that significantly correlated with the dependent variable and weakly correlated with each other: patient gender, chronic kidney disease with a decrease in glomerular filtration rate to 60 ml/min/1.73 m2, diabetic retinopathy, verified peripheral polyneuropathy, cigarette smoking 1 pack or more, the number of hemodynamically significant coronary artery stenoses according to the results of selective  coronary angiography, the use of short-acting insulin as part of hypoglycemic therapy, the use of long-acting insulin as part of hypoglycemic therapy. </p></sec><sec><title>Conclusion</title><p>Conclusion. The study demonstrates the high predictive ability of the author’s approach for determining the individual predicted time for the development of AMI in a patient with type 2 DM. The introduction of the developed method into real clinical practice will make it possible to personally manage type 2 DM patients and to reduce the individual risk of such a formidable cardiovascular complication as myocardial infarction. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>риск инфаркта миокарда</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>прогнозирование времени развития острого инфаркта миокарда</kwd></kwd-group><kwd-group xml:lang="en"><kwd>risk of myocardial infarction</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>predicting the time of acute myocardial infarction development</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rawshani A., Rawshani A., Franzén S., Sattar N., Eliasson B., Svensson A.M., Zethelius B., Miftaraj M., McGuire D.K., Rosengren A., Gudbjörnsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2018; 379 (7): 633–644. doi: 10.1056/NEJMoa1800256</mixed-citation><mixed-citation xml:lang="en">Rawshani A., Rawshani A., Franzén S., Sattar N., Eliasson B., Svensson A.M., Zethelius B., Miftaraj M., McGuire D.K., Rosengren A., Gudbjörnsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2018; 379 (7): 633–644. doi: 10.1056/NEJMoa1800256</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lejay A., Fang F., John R., Van J.A., Barr M., Thaveau F., Chakfe N., Geny B., Scholey J.W. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J. Mol. Cell. Cardiol., 2016 Feb; 91: 11–22. doi: 10.1016/j.yjmcc.2015.12.020</mixed-citation><mixed-citation xml:lang="en">Lejay A., Fang F., John R., Van J.A., Barr M., Thaveau F., Chakfe N., Geny B., Scholey J.W. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J. Mol. Cell. Cardiol., 2016 Feb; 91: 11–22. doi: 10.1016/j.yjmcc.2015.12.020</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sathyapalan T. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab. Vasc. Dis. Res., 2019 Nov; 16 (6): 489–497. doi: 10.1177/1479164119845561</mixed-citation><mixed-citation xml:lang="en">Sathyapalan T. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab. Vasc. Dis. Res., 2019 Nov; 16 (6): 489–497. doi: 10.1177/1479164119845561</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V., Federici M., Filippatos G., Grobbee D.E., Hansen T.B., Huikuri H.V., Johansson I., Juni P., Lettino M., Marx N., Mellbin L.G., Ostgren C.J., Rocca B., Roffi M., Sattar N., Seferovic P.M., Sousa-Uva M., Valensi P., Wheeler D.C., Group E.S.C.S.D. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J., 2020; 41 (2): 255–323. doi: 10.1093/eurheartj/ehz486</mixed-citation><mixed-citation xml:lang="en">Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V., Federici M., Filippatos G., Grobbee D.E., Hansen T.B., Huikuri H.V., Johansson I., Juni P., Lettino M., Marx N., Mellbin L.G., Ostgren C.J., Rocca B., Roffi M., Sattar N., Seferovic P.M., Sousa-Uva M., Valensi P., Wheeler D.C., Group E.S.C.S.D. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J., 2020; 41 (2): 255–323. doi: 10.1093/eurheartj/ehz486</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Гарганеева А.А., Кужелева Е.А., Борель К.Н., Кондратьева Д.С., Афанасьев С.А. Сахарный диабет 2 типа и острый инфаркт миокарда: прогностические варианты взаимодействия у пациентов разных возрастных групп. Сахарный диабет, 2018; 21 (2): 105–112. doi: 10.14341/DM8828</mixed-citation><mixed-citation xml:lang="en">Garganeeva A.A., Kuzheleva E.A., Borel K.N., Kondratyeva D.S., Afanasiev S.A. Diabetes mellitus type 2 and acute myocardial infarction: prognostic options for interaction in patients of different age groups. Diabetes Mellitus., 2018; 21 (2): 105–112. (In Russ.) doi: 10.14341/DM8828</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Марданов Б.У., Пяк В.Е., Корнеева М.Н., Ахмедова Э.Б. Влияние сахарного диабета на течение и исход инфаркта миокарда у больных, подвергнутых чрескожным коронарным вмешательствам. Кардиоваскуляр. терапия и профилактика, 2016; 15 (6): 13–18. doi: 10.15829/1728-8800-2016-6-13-18</mixed-citation><mixed-citation xml:lang="en">Mardanov B.U., Pyak V.Е., Korneeva M.N., Akhmedova E.B. The influence of diabetes mellitus on the course and outcomes of myocardial infarction in patients undergoing percutaneous coronary interventions. Cardiovascular Therapy and Prevention, 2016; 15 (6): 13–18. (In Russ.) doi: 10.15829/1728-8800-2016-6-13-18</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M.J., Prescott E., Roffi M., Valgimigli M., Varenhorst C., Vranckx P., Widimsky P., Group E.S.C.S.D. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart. J., 2018; 39 (2): 119–177. doi: 10.1093/eurheartj/ehx393</mixed-citation><mixed-citation xml:lang="en">Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M.J., Prescott E., Roffi M., Valgimigli M., Varenhorst C., Vranckx P., Widimsky P., Group E.S.C.S.D. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart. J., 2018; 39 (2): 119–177. doi: 10.1093/eurheartj/ehx393</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Юнкеров В.И., Григорьев С.Г. Математико-статистическая обработка данных медицинских исследований. СПб.: ВМедА, 2002. 266 с.</mixed-citation><mixed-citation xml:lang="en">Yunkerov V.I., Grigorev S.G. Mathematical and statistical processing of medical research data. S.-Petersburg: VMedA, 2002. P. 266. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Воскобойников Ю.Е. Эконометрика в Excel: парные и множественные регрессионные модели. СПб.: Лань, 2016. 260 с.</mixed-citation><mixed-citation xml:lang="en">Voskoboinikov Yu.E. Econometrics in Excel: Paired and Multiple Regression Models. S.-Petersburg: Lan’, 2016. P. 260. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Edqvist J., Rawshani A., Adiels M., Björck L., Lind M., Svensson A.M., Gudbjörnsdottir S., Sattar N., Rosengren A. Contrasting associations of body mass index and hemoglobin A1c on the excess risk of acute myocardial infarction and heart failure in type 2 diabetes mellitus. J. Am. Heart Assoc., 2019; 8 (24): e013871. doi: 10.1161/JAHA.119.013871</mixed-citation><mixed-citation xml:lang="en">Edqvist J., Rawshani A., Adiels M., Björck L., Lind M., Svensson A.M., Gudbjörnsdottir S., Sattar N., Rosengren A. Contrasting associations of body mass index and hemoglobin A1c on the excess risk of acute myocardial infarction and heart failure in type 2 diabetes mellitus. J. Am. Heart Assoc., 2019; 8 (24): e013871. doi: 10.1161/JAHA.119.013871</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) eye study group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) study group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care, 2016; 39 (7): 1089–1100. doi: 10.2337/dc16-0024</mixed-citation><mixed-citation xml:lang="en">Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) eye study group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) study group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care, 2016; 39 (7): 1089–1100. doi: 10.2337/dc16-0024</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Agashe S., Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey. Cardiovasc. J., 2018; 14 (4): 251–256. doi: 10.14797/mdcj-14-4-251</mixed-citation><mixed-citation xml:lang="en">Agashe S., Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey. Cardiovasc. J., 2018; 14 (4): 251–256. doi: 10.14797/mdcj-14-4-251</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ruospo M., Saglimbene V.M., Palmer S.C., de Cosmo S., Pacilli A., Lamacchia O., Cignarelli M., Fioretto P., Vecchio M., Craig J.C., Strippoli G.F. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst. Rev., 2017; 6 (6): CD010137. doi: 10.1002/14651858.CD010137.pub2</mixed-citation><mixed-citation xml:lang="en">Ruospo M., Saglimbene V.M., Palmer S.C., de Cosmo S., Pacilli A., Lamacchia O., Cignarelli M., Fioretto P., Vecchio M., Craig J.C., Strippoli G.F. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst. Rev., 2017; 6 (6): CD010137. doi: 10.1002/14651858.CD010137.pub2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lo C., Toyama T., Wang Y., Lin J., Hirakawa Y., Jun M., Cass A., Hawley C.M., Pilmore H., Badve S.V., Perkovic V., Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst.</mixed-citation><mixed-citation xml:lang="en">Lo C., Toyama T., Wang Y., Lin J., Hirakawa Y., Jun M., Cass A., Hawley C.M., Pilmore H., Badve S.V., Perkovic V., Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst. Rev., 2018; 9 (9): CD011798. doi: 10.1002/14651858.CD011798.pub2</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rev., 2018; 9 (9): CD011798. doi: 10.1002/14651858.CD011798.pub2</mixed-citation><mixed-citation xml:lang="en">Dasgupta I., Singh A.K. Review: In diabetes, intensive and standard glycemic control do not differ for endstage kidney disease or death. Ann. Intern. Med., 2017; 167 (8): JC47. doi: 10.7326/ACPJC-2017-167-8-047</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dasgupta I., Singh A.K. Review: In diabetes, intensive and standard glycemic control do not differ for endstage kidney disease or death. Ann. Intern. Med., 2017; 167 (8): JC47. doi: 10.7326/ACPJC-2017-167-8-047</mixed-citation><mixed-citation xml:lang="en">Cushman W.C., Whelton P.K., Fine L.J., Wright J.T.Jr, Reboussin D.M., Johnson K.C., Oparil S.; SPRINT Study Research Group. SPRINT trial results: Latest news in hypertension management. Hypertension, 2016; 67 (2): 263–265. doi: 10.1161/hypertensionaha.115.06722</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cushman W.C., Whelton P.K., Fine L.J., Wright J.T.Jr, Reboussin D.M., Johnson K.C., Oparil S.; SPRINT Study Research Group. SPRINT trial results: Latest news in hypertension management. Hypertension, 2016; 67 (2): 263–265. doi: 10.1161/hypertensionaha.115.06722</mixed-citation><mixed-citation xml:lang="en">Cushman W.C., Whelton P.K., Fine L.J., Wright J.T.Jr, Reboussin D.M., Johnson K.C., Oparil S.; SPRINT Study Research Group. SPRINT trial results: Latest news in hypertension management. Hypertension, 2016; 67 (2): 263–265. doi: 10.1161/hypertensionaha.115.06722</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
